These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 23727135

  • 1. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
    Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A, Mimura M, Uchida H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug 01; 45():178-82. PubMed ID: 23727135
    [Abstract] [Full Text] [Related]

  • 2. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Plitman E, Chung JK, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Rajji TK, Mamo DC, Graff-Guerrero A.
    J Clin Psychiatry; 2016 Dec 01; 77(12):e1557-e1563. PubMed ID: 28086010
    [Abstract] [Full Text] [Related]

  • 3. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, Maeda J, Okubo Y, Suhara T.
    J Clin Psychiatry; 2010 Sep 01; 71(9):1131-7. PubMed ID: 20361897
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.
    JAMA Psychiatry; 2015 Sep 01; 72(9):927-34. PubMed ID: 26131622
    [Abstract] [Full Text] [Related]

  • 5. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H.
    Schizophr Res; 2013 Nov 01; 150(2-3):373-9. PubMed ID: 24028745
    [Abstract] [Full Text] [Related]

  • 6. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
    Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H.
    Schizophr Bull; 2013 May 01; 39(3):564-74. PubMed ID: 22290266
    [Abstract] [Full Text] [Related]

  • 7. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA.
    Schizophr Res; 2009 Feb 01; 107(2-3):218-22. PubMed ID: 19038534
    [Abstract] [Full Text] [Related]

  • 8. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S, Zipursky RB, Remington G.
    Am J Psychiatry; 1999 Feb 01; 156(2):286-93. PubMed ID: 9989565
    [Abstract] [Full Text] [Related]

  • 9. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.
    Takeuchi H, Suzuki T, Bies RR, Remington G, Watanabe K, Mimura M, Uchida H.
    J Clin Psychiatry; 2014 Nov 01; 75(11):1209-14. PubMed ID: 25099201
    [Abstract] [Full Text] [Related]

  • 10. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
    Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Mimura M, Uchida H.
    Schizophr Res; 2014 Mar 01; 153(1-3):184-8. PubMed ID: 24491908
    [Abstract] [Full Text] [Related]

  • 11. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
    Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A.
    Psychopharmacology (Berl); 2004 Oct 01; 175(4):473-80. PubMed ID: 15083259
    [Abstract] [Full Text] [Related]

  • 12. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo D, Uchida H.
    J Clin Psychiatry; 2012 Aug 01; 73(8):1147-52. PubMed ID: 22967779
    [Abstract] [Full Text] [Related]

  • 13. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
    Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H.
    J Clin Psychopharmacol; 2013 Oct 01; 33(5):682-5. PubMed ID: 23899638
    [Abstract] [Full Text] [Related]

  • 14. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.
    Yasui-Furukori N, Saito M, Nakagami T, Sugawara N, Sato Y, Tsuchimine S, Furukori H, Kaneko S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):537-40. PubMed ID: 20170699
    [Abstract] [Full Text] [Related]

  • 15. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.
    Am J Psychiatry; 2004 May 16; 161(5):818-25. PubMed ID: 15121646
    [Abstract] [Full Text] [Related]

  • 16. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML, Shen WW, Chen CH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec 12; 32(8):1978-81. PubMed ID: 18848860
    [Abstract] [Full Text] [Related]

  • 17. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.
    Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr 27; 37(1):182-7. PubMed ID: 22230651
    [Abstract] [Full Text] [Related]

  • 18. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, Correll C, Soares JC, Yang FD, Wang SL, Zhang XY.
    Psychoneuroendocrinology; 2015 Aug 27; 58():130-40. PubMed ID: 25981348
    [Abstract] [Full Text] [Related]

  • 19. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.
    de Haan L, Booij J, Lavalaye J, van Amelsvoort T, Linszen D.
    Psychopharmacology (Berl); 2006 Jan 27; 183(4):500-5. PubMed ID: 16292589
    [Abstract] [Full Text] [Related]

  • 20. [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].
    Wyszogrodzka-Kucharska A, Kunert-Radek J, Rabe-Jabłońska J.
    Psychiatr Pol; 2005 Jan 27; 39(6):1143-55. PubMed ID: 16526181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.